• Users Online: 94
  • Print this page
  • Email this page
REVIEW ARTICLE
Year : 2022  |  Volume : 12  |  Issue : 3  |  Page : 249-263

What's new in neuromyelitis optica spectrum disorder treatment?


1 Department of Ophthalmology, Far Eastern Memorial Hospital, New Taipei City, Taiwan
2 Department of Electrical Engineering, Yuan Ze University, Chung-Li, Taoyuan, Taiwan

Correspondence Address:
Dr. Tzu-Lun Huang
No. 21, Section 2, Nanya South Road, Banqiao District, New Taipei City 22060
Taiwan
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2211-5056.355617

Rights and Permissions

Optic neuritis, an optic nerve inflammatory disease presenting with acute unilateral or bilateral visual loss, is one of the core symptoms of neuromyelitis optica spectrum disorder (NMOSD). The diagnosis of NMOSD-related optic neuritis is challenging, and it is mainly based on clinical presentation, optical coherence tomography, magnetic resonance imaging scans, and the status of serum aquaporin-4 antibodies. In the pathogenesis, aquaporin-4 antibodies target astrocytes in the optic nerves, spinal cord and some specific regions of the brain eliciting a devastating autoimmune response. Current pharmacological interventions are directed against various steps within the immunological response, notably the terminal complement system, B-cells, and the pro-inflammatory cytokine Interleukin 6 (IL6). Conventional maintenance therapies were off-label uses of the unspecific immunosuppressants azathioprine and mycophenolate mofetil as well as the CD20 specific antibody rituximab and the IL6 receptor specific antibody tocilizumab. Recently, four phase III clinical trials demonstrated the safety and efficacy of the three novel biologics eculizumab, inebilizumab, and satralizumab. These monoclonal antibodies are directed against the complement system, CD19 B-cells and the IL6 receptor, respectively. All three have been approved for NMOSD in the US and several other countries worldwide and thus provide convincing treatment options.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed385    
    Printed6    
    Emailed0    
    PDF Downloaded65    
    Comments [Add]    

Recommend this journal